TABLE 3 ] .
Prognostic Value of Plasma Biomarkers in Single-Center and Multicenter Studies
| Biomarker, per 1-Log Increment | Death | P Value |
| Single center | ||
| IL-8 | 1.65 (1.25-2.17) | < .001 |
| IL-6 | 1.81 (1.34-2.45) | < .001 |
| SP-Da | 1.33 (0.82-2.14) | .25 |
| RAGE | 1.98 (1.18-3.33) | .01 |
| Ang-2 | 2.54 (1.38-4.68) | .003 |
| Multicenter | ||
| IL-8 | 1.41 (1.27-1.57) | < .001 |
| IL-6 | 1.24 (1.14-1.35) | < .001 |
| SP-D | 1.09 (0.95-1.24) | .23 |
| RAGE | 1.16 (1.003-1.34) | .045 |
| Ang-2b | 1.43 (1.19-1.73) | < .001 |
| vWF | 1.83 (1.46-2.30) | < .001 |
Data are presented as OR (95% CI). See Table 2 legend for expansion of abbreviations.
a
OR for mortality in indirect ARDS, 0.99 (95% CI, 0.52-1.91; P = .98); OR for mortality in direct ARDS, 2.26 (95% CI, 0.94-5.45; P = .07). Test of interaction P = .14. There was no evidence for interaction for any other biomarker in the single-center data.
b
OR for mortality in indirect ARDS, 1.17 (95% CI, 0.85-1.62; P = .33); OR for mortality in direct ARDS, 1.51 (95% CI, 1.19-1.91; P = .001). Test of interaction P = .22. There was no evidence for interaction for any other biomarker in the multicenter data.